Health Canada Approves Taltz for Active Ankylosing Spondylitis

Health Canada approved Eli Lilly’s Taltz (ixekizumab) for the treatment of adults with active ankylosing spondylitis who have responded inadequately to, or are intolerant to, conventional therapy.

The approval was based on the results of two phase 3 clinical trials, which showed that patients treated with Taltz achieved statistically significant improvements in symptoms of the rare spinal arthritis compared to placebo.

Taltz was previously approved by Health Canada for moderate to severe plaque psoriasis and psoriatic arthritis.